1. Home
  2. VRAX vs GRNQ Comparison

VRAX vs GRNQ Comparison

Compare VRAX & GRNQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$2.40

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Logo Greenpro Capital Corp.

GRNQ

Greenpro Capital Corp.

HOLD

Current Price

$10.55

Market Cap

23.6M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRAX
GRNQ
Founded
2013
2013
Country
United Kingdom
Malaysia
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.1M
23.6M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
VRAX
GRNQ
Price
$2.40
$10.55
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
★ $1.00
N/A
AVG Volume (30 Days)
30.1K
★ 136.3K
Earning Date
06-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $3,673,997.00
Revenue This Year
$217,274.83
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 24.55
52 Week Low
$0.10
$1.04
52 Week High
$13.19
$22.70

Technical Indicators

Market Signals
Indicator
VRAX
GRNQ
Relative Strength Index (RSI) 41.64 48.80
Support Level $0.18 $1.51
Resistance Level $3.01 $14.40
Average True Range (ATR) 0.19 2.38
MACD -0.01 -0.52
Stochastic Oscillator 32.26 11.89

Price Performance

Historical Comparison
VRAX
GRNQ

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China, and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust, & wealth management. Its segments include the Service business engaged in the provision of corporate advisory & business solution services; the Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong & Malaysia; & the Digital business segment engaged in the provision of digital platform & trading of digital assets.

Share on Social Networks: